Skye Bioscience Inc.(SKYE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

Skye Bioscience Inc.(SKYE)

12.05-0.20-1.67%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake
  Simply Wall St. · 05-12
  Skye Bioscience, Inc.'s (NASDAQ:SKYE) last week's 13% decline must have disappointed private equity firms who have a significant stake
- BRIEF-Skye Bioscience Files For Mixed Shelf Of Up To $300 Mln
  Reuters · 05-11
  BRIEF-Skye Bioscience Files For Mixed Shelf Of Up To $300 Mln
- Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
  GlobeNewswire · 05-10
  Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
- How the Medical Industry Could Produce the Biggest AI Stock Winners
  InvestorPlace · 05-07
  How the Medical Industry Could Produce the Biggest AI Stock Winners
- Skye Bioscience to Present at Upcoming Investment Conferences
  GlobeNewswire · 04-23
  Skye Bioscience to Present at Upcoming Investment Conferences
- These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
  InvestorPlace · 04-20
  These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
- These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
  InvestorPlace · 04-17
  These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
- Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
  seekingalpha · 04-12
  Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
- Skye Bioscience to uplist to Nasdaq Global Market
  seekingalpha · 04-10
  Skye Bioscience to uplist to Nasdaq Global Market
- Skye Bioscience Strengthens Nasdaq Compliance with Pro Forma Balance Sheet
  TIPRANKS · 04-04
  Skye Bioscience Strengthens Nasdaq Compliance with Pro Forma Balance Sheet
- Skye Bioscience Price Target Raised to $20.00/Share From $12.00 by Piper Sandler
  Dow Jones · 03-14
  Skye Bioscience Price Target Raised to $20.00/Share From $12.00 by Piper Sandler
- Skye Bioscience looks to raise $40M in a private placement equity
  seekingalpha · 03-11
  Skye Bioscience looks to raise $40M in a private placement equity
- How the Medical Industry Could Produce the Biggest AI Stock Winners
  InvestorPlace · 03-06
  How the Medical Industry Could Produce the Biggest AI Stock Winners
- Skye Bioscience Announces Board Expansion and Leadership Changes
  TIPRANKS · 03-05
  Skye Bioscience Announces Board Expansion and Leadership Changes
- Medical marijuana market expected to grow at 22% CAGR through 2027
  seekingalpha · 03-03
  Medical marijuana market expected to grow at 22% CAGR through 2027
- Skye Bioscience Nears Nasdaq Listing with Updated Finances
  TIPRANKS · 02-13
  Skye Bioscience Nears Nasdaq Listing with Updated Finances
- Skye Bioscience to Present at Oppenheimer Investor Conference
  StreetInsider · 02-07
  Skye Bioscience to Present at Oppenheimer Investor Conference
- Skye Bioscience Initiated at Overweight by Piper Sandler
  Dow Jones · 02-05
  Skye Bioscience Initiated at Overweight by Piper Sandler
Company Profile
Company Name
Skye Bioscience Inc.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.skyebioscience.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
- 05-10
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 04-10
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 04-10
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 04-10
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 04-04
  [Amend]Public Prospectus
  Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
  Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
- 04-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-27
  Public Prospectus
  Form S-1 - General form for registration of securities under the Securities Act of 1933
  Form S-1 - General form for registration of securities under the Securities Act of 1933
- 03-22
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-13
  Beneficial Ownership Change
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
- 03-13
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 03-04
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 02-12
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 02-08
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 02-03
  Beneficial Ownership Change
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 01-31
  Beneficial Ownership Change
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
  Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]

1D
5D
Day
Week
Month

High

12.53

Open

12.05

Volume%

0.31

Low

12.01

12.25

T/O Rate

0.12%

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

Skye Bioscience Inc.(SKYE)

Company Profile

Most Discussed